title: The high frequency of HIV type 1-specific cellular immune responses in seronegative individuals with parenteral and/or heterosexual HIV type 1 exposure.
abstract: Some individuals remain HIV seronegative despite repeated unprotected exposure to the virus. Recent observations led to a concept that acquired immunity plays a role in protection or at least in altered susceptibility to HIV-1 infection in highly exposed seronegative (ESN) individuals. Our aim was to study HIV-specific cellular immune responses induced in parenterally and/or heterosexually ESN individuals. Nine seronegative injection drug users (IDUs), 10 seronegative individuals, and nine of their HIV-positive sexual and/or IDU partners from the cohort of IDUs were included in the study. The discordant couples had unprotected sex, and some of seronegative partners also had parenteral exposure. Cell-mediated responses were measured in peripheral blood mononuclear cells (PBMCs) by ex vivo interferon (IFN)-γ-ELISpot and ICS combining IFN-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-2 after stimulation with four consensus peptide pools (Nef, Gag, RT, Env, subtype A-EE). Thirteen out of 19 (68%) seronegative study subjects had strong Nef peptide pool-specific ELISpot responses, three (16%) subjects responded against the Gag peptide pool, and one subject had an RT peptide pool response. Nef peptide pool responses in ESN were as high as in seropositive subjects. The multiple HIV-specific cytokine production in both CD4(+) and CD8(+) T cells was shown for several ESN subjects. The functional profiles of the immune responses were different between seronegative and HIV-positive study groups. Whether the observed cellular responses have any protective role against HIV needs to be further investigated.
authors.affiliation: Biomedical Center and St. Petersburg State University, St. Petersburg, Russia.
authors.forename: Boris V
authors.initials: BV
authors.lastname: Murashev
authors.forename: Olga V
authors.initials: OV
authors.lastname: Nazarenko
authors.forename: Ekaterina B
authors.initials: EB
authors.lastname: Akulova
authors.forename: Anna K
authors.initials: AK
authors.lastname: Artemyeva
authors.forename: Sergey V
authors.initials: SV
authors.lastname: Verevochkin
authors.forename: Alla V
authors.initials: AV
authors.lastname: Shaboltas
authors.forename: Roman V
authors.initials: RV
authors.lastname: Skochilov
authors.forename: Olga V
authors.initials: OV
authors.lastname: Toussova
authors.forename: Andrei P
authors.initials: AP
authors.lastname: Kozlov
mesh_terms: D000328:Adult; D016207:Cytokines / Q000378:metabolism; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D018023:HIV Seronegativity / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D020010:Heterosexuality; D006801:Humans; D007111:Immunity, Cellular; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015819:Substance Abuse, Intravenous / Q000150:complications*; D055815:Young Adult
chemical_list: D016207:Cytokines